(ALBANY, US) Delveinsight has launched a new report on Multiple System Atrophy Epidemiology

DelveInsight’s Multiple System Atrophy Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple System Atrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by acombination of symptoms that affect both the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. The initial symptoms of MSA are often difficult to distinguish from the initial symptoms of Parkinson’s disease and include: slowness of movement, tremor, or rigidity (stiffness); clumsiness or incoordination; impaired speech, a croaky, quivering voice; fainting or lightheadedness due to orthostatic hypotension; bladder control problems, such as a sudden urge to urinate or difficulty emptying the bladder.

Request for Free Sample Page:- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-epidemiology-forecast

Multiple System Atrophy Epidemiology

Multiple system atrophy (MSA) is a rare neurodegenerative disorder that presents with a variable combination of autonomic, cerebellar, parkinsonian and pyramidal features . MSA is an orphan disease with an incidence of upto 2.4 cases per 100 000 persons per year, while the prevalence may reach up to 7.8 patients per 100 000 population over the age of 40. The MSA‐P variant seems to be more common in the western hemisphere, whereas MSA‐C appears to be more frequent in Asia . The future studies on MSA will need to focus on better understanding of the triggers of the disease process, as well as on improved diagnosis, with identification of early biomarkers that may allow the timely initiation of disease modifying therapies with beneficial effects on disease progression.

The Multiple System Atrophy (MSA) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Multiple System Atrophy (MSA) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Multiple System Atrophy (MSA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 Key facts of the report

• MSA appears to affect males and females in equal numbers. The peak onset of MSA is between 55-60 years of age, with a range from 30 to over 90 years.
• A prevalence study in London, UK, gave an age-adjusted figure of 4.4 living cases per 100,000 population at any one time, which would currently translate to about 14,000 living cases in the USA.
• There is about 1 living case of MSA in the population for every 40 cases of Parkinson’s disease, but because survival in MSA is shorter than for PD, about 1 new MSA case presents every year for aboutevery 20 who present with PD.

Table of content

1. Key Insights 

2. Executive Summary of Multiple System Atrophy (MSA)

3. Multiple System Atrophy (MSA): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 Related Reports

Multiple System Atrophy (MSA) – Pipeline Insights, 2020

Multiple System Atrophy (MSA) Market Insight, Epidemiology and Market Forecast -2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/